Oruka Therapeutics (ORKA) Current Assets (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Current Assets of $395.2 million for Q1 2026, up 12.26% year-over-year from $352.1 million in Q1 2025, and up 14.95% quarter-over-quarter from $343.9 million in Q4 2025.
Oruka Therapeutics (ORKA) Current Assets (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $395.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 12.26% year-over-year to $395.2 million; the TTM figure through Mar 2026 stood at $395.2 million (up 12.26% YoY), while the FY2025 annual figure was $343.9 million, down 8.76% from the prior year.
- Current Assets for Q1 2026 stood at $395.2 million, up from $343.9 million in the prior quarter.
- The five-year high for Current Assets was $412.9 million in Q3 2024, with the low at $33.8 million in Q2 2024.
- The 5-year median for Current Assets is $47.7 million (2022), against an average of $175.5 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets slipped 26.47% in 2022, then soared 961.78% in 2024.
- Oruka Therapeutics' Current Assets stood at $42.7 million in 2022, then decreased by 11.96% to $37.6 million in 2023, then surged by 902.52% to $376.9 million in 2024, then decreased by 8.76% to $343.9 million in 2025, then advanced by 14.95% to $395.2 million in 2026.
- Business Quant data shows ORKA's Current Assets at $395.2 million in Q1 2026, $343.9 million in Q4 2025, and $355.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 884.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 884.56 Mn |
| Mar 31, 2026 | 395.25 Mn |
| Dec 31, 2025 | 343.86 Mn |
| Sep 30, 2025 | 355.16 Mn |
| Jun 30, 2025 | 332.01 Mn |
| Mar 31, 2025 | 352.08 Mn |
| Dec 31, 2024 | 376.87 Mn |
| Sep 30, 2024 | 412.95 Mn |
| Jun 30, 2024 | 33.82 Mn |
| Mar 31, 2024 | 36.67 Mn |
| Dec 31, 2023 | 37.59 Mn |
| Sep 30, 2023 | 38.89 Mn |
| Jun 30, 2023 | 40.76 Mn |
| Mar 31, 2023 | 41.70 Mn |
| Dec 31, 2022 | 42.70 Mn |
| Sep 30, 2022 | 44.55 Mn |
| Jun 30, 2022 | 47.66 Mn |
| Mar 31, 2022 | 50.54 Mn |
| Dec 31, 2021 | 54.42 Mn |
| Sep 30, 2021 | 59.67 Mn |